Zyprexa

* Lilly disclosed encouraging Phase II results for both enzastaurin for non-Hodgkin's lymphoma and Factor Xa inhibitor for thrombotic disorders.

* Lilly and Alkermes, Inc.

signed an agreement to develop and commercialize inhaled formulations of parathyroid hormone.

This marks the third collaboration between the companies.

* Lilly licensed from Kyowa Hakko Kogyo Co., Ltd.

an anticancer drug candidate that inhibits the mitotic kinesin Eg5.

Lilly received an exclusive license to develop and sell the compound worldwide except in Japan, with Lilly and Kyowa Hakko sharing rights in certain Asian countries.

* Lilly, the Departmen...

Read more...